Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for…
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this…
AstraZeneca has announced positive results from the pivotal phase III MIRANDA trial of tozorakimab, a groundbreaking first-in-class monoclonal antibody designed to treat Chronic Obstructive Pulmonary Disease (COPD). According to PharmaBiz.com,…
The US Food and Drug Administration (FDA) has approved Idvynso, a groundbreaking two-drug single-tablet regimen combining 100 mg doravirine and 0.25 mg islatravir, for treating HIV-1 infection in adults. As…
Health Canada has officially approved Cysklar® (cysteamine ophthalmic solution) 0.44%, marking a significant breakthrough for Canadians living with cystinosis. According to BusinessWire.com, the approval enables patients to access a topical…
Cancer cachexia represents one of oncology's most overlooked catastrophes. Patients waste away, lose appetite, and deteriorate despite receiving chemotherapy, yet few treatment options exist to address this metabolic collapse. According…
I had learned that the many twists and turns on our rare disease path were similar to the families we met Originally published on May 11, 2022, this article explores celebrates author…
Diabetic macular edema represents a silent threat to working professionals across America. The condition, which causes fluid accumulation in the macula, the eye's central focusing region, ranks as the leading…
The aesthetic skincare market has long overlooked a fundamental principle: skin preparation matters as much as the procedure itself. According to PharmaBiz.com, Galderma's Alastin brand is now challenging that assumption…
Pancreatic cancer remains one of medicine's most formidable challenges, and recent clinical developments suggest a potential turning point. Revolution Medicines presented compelling evidence this week that its experimental drug daraxonrasib…
AskBio Inc., a gene therapy subsidiary of pharmaceutical giant Bayer AG, has taken a significant step forward in advancing treatment options for Parkinson's disease. According to PharmaBiz.com, the company announced…
Fernando Mendoza's journey to becoming the Las Vegas Raiders' first overall NFL Draft pick is not a typical underdog narrative, it's a testament to resilience, maternal influence, and the power…
Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor for plaque psoriasis treatment.…
Lynk Pharmaceuticals announced a significant development in its pipeline with the China National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for zemprocitinib capsules to treat moderate-to-severe…
Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA's acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According…
IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal melanoma. According to BioSpace.com, the…
Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As reported by BusinesWire.com, the company…
A decade of accumulated clinical experience with nusinersen has culminated in a significant regulatory advancement. According to Pharma Times Online, Biogen's newly approved high-dose Spinraza regimen represents a thoughtful evolution…
Researchers have demonstrated substantial therapeutic benefits for brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, in adults with dermatomyositis, according to findings from a Phase 3 clinical trial published…
CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma…
Chugai Pharmaceutical Co., Ltd. announced that Roche has made the strategic decision to discontinue clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin antibody, for two neuromuscular conditions: spinal muscular…
Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology's most challenging cancers. As reported by Pharmaceutical Technology, the company…
The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model increasingly conflicts with the complex…
For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch that cannot be relieved by…
When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants, leaving them trapped in a…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
